Home » Stocks » OPNT

Opiant Pharmaceuticals, Inc. (OPNT)

Stock Price: $16.12 USD 0.52 (3.33%)
Updated Jul 30, 2021 4:00 PM EDT - Market closed
After-hours: $16.10 -0.02 (-0.12%) Jul 30, 4:31 PM
Market Cap 69.81M
Revenue (ttm) 31.73M
Net Income (ttm) -3.02M
Shares Out 4.33M
EPS (ttm) -0.71
PE Ratio n/a
Forward PE 26.74
Dividend n/a
Dividend Yield n/a
Trading Day July 30
Last Price $16.12
Previous Close $15.60
Change ($) 0.52
Change (%) 3.33%
Day's Open 15.60
Day's Range 15.60 - 16.39
Day's Volume 13,649
52-Week Range 6.79 - 19.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SANTA MONICA, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

1 week ago - GlobeNewsWire

SANTA MONICA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

2 weeks ago - GlobeNewsWire

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced top-line results from its confirmatory pharmacokinetic study for OPNT003, nasal nalmefene, for opioid overdose.  The 68-subject study compared 3mg nal...

3 weeks ago - Benzinga

SANTA MONICA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“PK”) stud...

3 weeks ago - GlobeNewsWire

SANTA MONICA, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, a...

2 months ago - GlobeNewsWire

SANTA MONICA, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdo...

2 months ago - GlobeNewsWire

Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 65.00% over the past year to ($0.66), wh...

2 months ago - Benzinga

SANTA MONICA, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdo...

2 months ago - GlobeNewsWire

SANTA MONICA, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, t...

2 months ago - GlobeNewsWire

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) wit...

3 months ago - Benzinga

SANTA MONICA, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug over...

3 months ago - GlobeNewsWire

SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug over...

4 months ago - GlobeNewsWire

SANTA MONICA, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug over...

4 months ago - GlobeNewsWire

Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q4 results. Quarterly Results Earnings per share decreased 180.00% over the past year to ($0.16), which missed the est...

4 months ago - Benzinga

SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug over...

4 months ago - GlobeNewsWire

SANTA MONICA, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...

5 months ago - GlobeNewsWire

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) doses the first patient in a confirmatory pharmacokinetic (PK) study evaluating OPNT003 (nasal nalmefene) for opioid overdose treatment. Results from the study ...

5 months ago - Benzinga

SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) st...

5 months ago - GlobeNewsWire

SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced...

7 months ago - GlobeNewsWire

SANTA MONICA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

7 months ago - GlobeNewsWire

SANTA MONICA, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

7 months ago - GlobeNewsWire

In this article we will check out the progression of hedge fund sentiment towards Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) and determine whether it is a good investment right now. We at Insider Monkey...

8 months ago - Insider Monkey

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of Opiant Pharmaceuticals (NASDAQ:OPNT) were flat after the company reported Q3 results. Quarterly Results Earnings per share fell 92.39% over the past year to $0.15, which beat the estimate of (...

8 months ago - Benzinga

SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overd...

8 months ago - GlobeNewsWire

SANTA MONICA, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...

8 months ago - GlobeNewsWire

SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma...

9 months ago - GlobeNewsWire

SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, ...

9 months ago - GlobeNewsWire

SANTA MONICA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose...

11 months ago - GlobeNewsWire

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

SANTA MONICA, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

11 months ago - GlobeNewsWire

SANTA MONICA, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose...

1 year ago - GlobeNewsWire

SANTA MONICA, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal...

1 year ago - GlobeNewsWire

Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SANTA MONICA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug over...

1 year ago - GlobeNewsWire

Opiant Pharmaceuticals' (OPNT) CEO Roger Crystal on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SANTA MONICA, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

1 year ago - GlobeNewsWire

SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

1 year ago - GlobeNewsWire

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

SANTA MONICA, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug ove...

1 year ago - GlobeNewsWire

SANTA MONICA, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdos...

1 year ago - GlobeNewsWire

Based on our model, the value of Narcan Nasal Spray royalty alone should be worth anywhere from $11.6 to $27.5.

1 year ago - Seeking Alpha

SANTA MONICA, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose...

1 year ago - GlobeNewsWire

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Trump takes on high drug prices

YouTube video

Opiant Pharmaceuticals CEO Roger Crystal on President Trump's calls to lower drug prices.

Other stocks mentioned: ABBV, GSK, JNJ, MRK, NVS, PFE, SNY ...
3 years ago - Fox Business

About OPNT

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorpo... [Read more...]

Industry
Biotechnology
Founded
2005
Stock Exchange
NASDAQ
Ticker Symbol
OPNT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for OPNT stock is "Strong Buy." The 12-month stock price forecast is 41.33, which is an increase of 156.39% from the latest price.

Price Target
$41.33
(156.39% upside)
Analyst Consensus: Strong Buy